ARVN Arvinas Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARVN

Price (delayed)

$32.12

Market cap

$2.19B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.62

Enterprise value

$1.87B

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing ...

Highlights
The quick ratio has surged by 53% since the previous quarter and by 20% year-on-year
The company's equity rose by 44% QoQ and by 17% YoY
The gross profit has plunged by 51% from the previous quarter and by 40% YoY
Arvinas's revenue has plunged by 51% from the previous quarter and by 40% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://arvinas.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ARVN
Market
Shares outstanding
68.08M
Market cap
$2.19B
Enterprise value
$1.87B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.68
Price to sales (P/S)
22.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.86
Earnings
Revenue
$78.5M
EBIT
-$366.4M
EBITDA
-$359.7M
Free cash flow
-$350.7M
Per share
EPS
-$6.62
Free cash flow per share
-$6.32
Book value per share
$11.99
Revenue per share
$1.41
TBVPS
$23.51
Balance sheet
Total assets
$1.3B
Total liabilities
$644.6M
Debt
$3.2M
Equity
$660M
Working capital
$1.02B
Liquidity
Debt to equity
0
Current ratio
4.98
Quick ratio
4.95
Net debt/EBITDA
0.87
Margins
EBITDA margin
-458.2%
Gross margin
100%
Net margin
-467.9%
Operating margin
-511.5%
Efficiency
Return on assets
-31.8%
Return on equity
-70.2%
Return on invested capital
-52.2%
Return on capital employed
-35%
Return on sales
-466.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARVN stock price

How has the Arvinas stock price performed over time
Intraday
1.65%
1 week
-7.49%
1 month
-21.66%
1 year
18.39%
YTD
-21.96%
QTD
-22.19%

Financial performance

How have Arvinas's revenue and profit performed over time
Revenue
$78.5M
Gross profit
$78.5M
Operating income
-$401.5M
Net income
-$367.3M
Gross margin
100%
Net margin
-467.9%
Arvinas's operating margin has plunged by 162% from the previous quarter and by 155% YoY
The net margin has dropped by 153% since the previous quarter and by 118% year-on-year
ARVN's operating income has plunged by 53% YoY and by 29% from the previous quarter
The gross profit has plunged by 51% from the previous quarter and by 40% YoY

Growth

What is Arvinas's growth rate over time

Valuation

What is Arvinas stock price valuation
P/E
N/A
P/B
2.68
P/S
22.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.86
The EPS has contracted by 25% YoY and by 20% from the previous quarter
The stock's price to book (P/B) is 45% less than its 5-year quarterly average of 4.8 and 9% less than its last 4 quarters average of 2.9
The company's equity rose by 44% QoQ and by 17% YoY
The P/S is 63% above the last 4 quarters average of 13.7 but 57% below the 5-year quarterly average of 52.1
Arvinas's revenue has plunged by 51% from the previous quarter and by 40% YoY

Efficiency

How efficient is Arvinas business performance
The ROS has plunged by 161% from the previous quarter and by 134% YoY
The company's return on invested capital has shrunk by 106% YoY and by 36% QoQ
ARVN's return on equity has dropped by 60% year-on-year and by 19% since the previous quarter
ARVN's return on assets has dropped by 55% year-on-year and by 23% since the previous quarter

Dividends

What is ARVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARVN.

Financial health

How did Arvinas financials performed over time
ARVN's total assets is 102% more than its total liabilities
The quick ratio has surged by 53% since the previous quarter and by 20% year-on-year
ARVN's current ratio has soared by 53% QoQ and by 19% YoY
The debt is 100% smaller than the equity
The debt to equity has plunged by 100% from the previous quarter and by 100% YoY
The company's equity rose by 44% QoQ and by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.